HighTide Therapeutics (HKG:2511) completed patient enrollment for its dapagliflozin-controlled phase III clinical trial of its in-house developed gut-liver anti-inflammatory metabolic modulator, Berberine Ursodeoxycholate (HTD1801), for the treatment of patients with type 2 diabetes mellitus.
The trial had planned to enroll 358 subjects and is purposed to evaluate the efficacy of the drug compared with dapagliflozin in adult subjects with type 2 diabetes mellitus, a Thursday Hong Kong bourse filing said.
Final data from the trial is expected to come out in 2025, the filing said.
Berberine Ursodeoxycholate or HTD1801 is a gut-liver anti-inflammatory metabolic oral modulator being developed for the treatment of metabolic and digestive diseases.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.